Navigation Links
UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria

Charlottesville, Va., September 4, 2007 A University of Virginia researcher has been awarded a $3.6 million grant from the National Institute of Allergy and Infectious Diseases to combat a growing international health crisis.

Dr. Richard Guerrant, founder of UVas Center for Global Health, plans to take a unique approach to treating the bacterium Clostridium difficile, which is growing increasingly resistant to certain antibiotics that work against bacteria of the colon. Clostridium difficile (C. diff) is a bacterium that causes diarrhea and can lead to more serious intestinal conditions such as colitis.

This is a huge problem which has been getting worse since the mid-1980s. Previously healthy young people are becoming ill with the disease and the national mortality rate from the disease has more than doubled in the last few years, Guerrant says.

Patients who are most at risk from C. diff have traditionally been older or have taken antibiotics for an extended period of time. The antibiotics eradicate the beneficial bacteria which all people have in their digestive tract, leaving the drug resistant C. diff to flourish. An estimated 5 to 7 percent of residents of assisted living and nursing facilities are infected with the bacterium.

The Centers for Disease Control reports there have been C. diff outbreaks in hospitals in 23 states. The drug-resistant strain has been blamed for more than 100 deaths over an 18-month period at a hospital in Quebec. The bacteria are found in feces. Infection can occur when people touch items or surfaces contaminated with feces.

C. difficile produces two toxins which cause the body to react with diarrhea, fever, loss of appetite, nausea and abdominal pain. Because the bacterium is proving resistant to antibiotics, Guerrant proposes countering the effects of the toxins instead of targeting the bacterium.

The current treatments have been to try a new antibiotic on the bacterium, which kills even more of the beneficial bacteria and allows C. diff to continue ravaging the patients, Guerrant says. By rendering the toxins harmless, we hope we can keep the debilitating effects of C. diff from proving fatal.

Guerrant says pilot data show this approach has great promise and he plans to collaborate with other UVa scientists and a pharmaceutical company to develop the treatment.


Contact: David Foreman
University of Virginia Health System

Related medicine news :

1. Researchers urge caution in using ear tube surgery
2. Researchers Scale to assess the Severity of Epilepsy in Kids
3. Ecstasy shrinks brain!!-researchers unveil the secrets of MDMA.
4. New Hair in 15 Days Could Now Be A Possibility Say Researchers
5. Researchers at Cornell University as been reported using research fund by false claims
6. Researchers trick Alzheimers Enzyme
7. Researchers find new HIV hiding place
8. Gene researchers make Malaria-resistant mosquito
9. Researchers developed world’s smallest toothbrus
10. Researchers discover receptor cells that can cause epilepsy
11. 15 Anti-SARS Drugs Identified By China-Europe Team of Researchers
Post Your Comments:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... ... Comfort Keepers® of San Diego, CA is excited to announce they are ... drive cancer patients to and from their cancer treatments. Comfort Keepers provides quality ... and ongoing independence. Getting to and from medical treatments is one of the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Consumers have taken ... regulators/payers have placed more emphasis on patient outcomes. ... support programs in the pharmaceutical industry have evolved ... Consequently, pharmaceutical companies are focusing on becoming more ... providing products and services that improve health. ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
Breaking Medicine Technology: